Candel Therapeutics Inc (CADL)

[philaya]

rocket to space...
got some today.

[trader59]

Traded twice the O/S so far, up over 100% on equal buys and sells, yeah, nothing suspicious about that...
Computer generated wash trading in progress, don't get trapped.

[Invest-in-America]

CADL: Likely very nice run-up from right here now --- behind their impressive Cancer news. Should reach circa 160% in a little while.

[glenn1919]

CADL...............................................https://stockcharts.com/h-sc/ui?s=CADL&p=W&b=5&g=0&id=p86431144783

[TrendTrade2016]

STOP EATING GARABGE YA FAT SLOBS...THEN MAYBE YOUR PANCREAS WILL WORK...SMH...THE US IS SO FAT AND SICK ITS CRAZY

[axelvento]

HUGE Estimated median overall survival was 28.8 months in the CAN-2409 group versus only 12.5 months in the control group.

At 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients, after SoC chemoradiation and prior to surgery, versus only 16.7% in the control group. At 36 months, a survival rate of 47.6% was estimated in patients who received CAN-2409, together with SoC chemoradiation prior to surgery, versus only 16.7% in the control group.

Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.0 months from enrollment. Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-announces-positive-interim-data-randomized

[Awl416]

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

[axelvento]

Dr. Tak continued, “In 2024, we are expecting six data readouts across our three platforms, which include novel clinical and biomarker data in lung cancer, pancreatic cancer, and brain cancer, and a potentially registrational phase 3 clinical trial in prostate cancer. We look forward to sharing additional updates in the year ahead.”

https://www.biospace.com/article/releases/candel-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-corporate-highlights/?keywords=pancreatic+cancer+phase+3

[Monksdream]

CADL under $2

[Monksdream]

CADL under $2

[Agoura Guy]

WHAT ARE YOU TALKING ABOUT????? I TRADED THE DWAC SHORT SQUEEZE LAST MONTH!!!!!!!

[TrendTrade2016]

just admit you don't trade stocks because you don't know how and you lost a tonne trying...stick to your odtes cause thats all ya got

[Agoura Guy]

YOU'RE IN DENIAL.... LOOK WHAT I DID WITH MY MARCH 15TH $500 SPY PUTS TODAY!!!!!!!

[TrendTrade2016]

watch and learn maggot....don't ya wish you knew how to trade stocks and regret losing all your $$$ trying

[Agoura Guy]

BEWARE OF THE CRIMINAL PUMP AND DUMP SCAM ARTIST PUMPING THIS!!!!! HE'S UNDER SEC INVESTIGATION AND WILL END UP IN PRISON!!!!!!

HE SHORTS HIS OWN PUMPS!!!!!!!!!!!

[TrendTrade2016]

CADL...HERES THE 1.94 BREAK

[TrendTrade2016]

CADL...BREAK THAT 1.94 ITS GOING TO GET CRAZY AROUND HALIFAX!!!

[TrendTrade2016]

CADL....HERE WE GO...GET READY TO RUMBLE IN THE JUNGLE

[TrendTrade2016]

CADL....MONSTER IN THE MAKING ON FAST TRACK FDA

[TrendTrade2016]

CADL...BLASTING NORTH IN A BIG RED MARKET...NOBODY EVEN SEE THIS STCK....MY AI SCANNER WILL OUT PERFORM EVERYBODY

[TrendTrade2016]

CADL....BIO BEAST

[Zorro]

Starting to turn back up.

[subslover]

NEWS
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
NEEDHAM, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational adenovirus asset CAN-2409 plus prodrug (valacyclovir) for the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) to improve overall survival.

“We are pleased with the FDA's decision to grant Fast Track Designation for CAN-2409 in pancreatic cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel. “This milestone follows our first interim data report from the randomized phase 2 clinical trial in patients with borderline resectable PDAC that showed prolonged and sustained survival after experimental treatment with CAN-2409, especially when compared to real-world data on patients receiving radiotherapy treatment. Candel remains on track to release updated overall survival data from the interim analysis of this clinical trial in the second quarter of 2024. We are grateful to the patients, caregivers, investigators and clinical sites that have taken part in this clinical trial.”

In November 2023, the Company presented encouraging overall survival and immunological biomarker data based on an interim analysis of the randomized, phase 2 clinical trial of CAN-2409 plus prodrug together with standard of care (SoC) neoadjuvant chemoradiation followed by resection for borderline resectable non-metastatic PDAC at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. An estimated survival rate of 71.4% at both 24 and 36 months in patients who received 2 or 3 injections of the CAN-2409 plus prodrug regimen, together with SoC chemoradiation prior to surgery was observed, versus only 16.7% estimated survival at both 24 and 36 months in patients treated with SoC chemoradiation prior to surgery alone. In parallel, the immunological changes observed in the resected pancreatic tissue after CAN-2409 administration suggested that this investigational treatment can activate an effective immunologic antitumoral response in this otherwise “cold” tumor.

About Candel Therapeutics

[Awl416]

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer

[axelvento]

Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 10, 2022

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-third-quarter-2022-financial-results



On December 6, the Company will hold its virtual R&D Day with leadership and renowned oncology experts to present an in-depth overview of the Company’s viral immunotherapy platforms and clinical pipeline including additional data from its phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV non-small cell lung cancer.

[subslover]

Hey axe, thank you for the beautiful info. I put my $$$$ in this with the expectation that we get a major run.

[axelvento]

November and December news in release!!!! Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma


CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.

but we will have more new data and a new cohort of 11 patients in December this year."

https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment

[subslover]

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
November 07 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.
Details are as follows:

37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Poster Presentation Title: Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice

Presenter: Anne R. Diers, PhD, Director of Early Research, Candel Therapeutics
Abstract Number: 1134
Date/Time: Friday, November 11, 2022, from 9 am – 8:30 pm ET
Location: Hall C, Omni Boston Hotel, Boston, MA or Virtual

Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

Presenter: Patrick Y. Wen, MD, Director, Cancer for Neuro-Oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; Principal Investigator for Candel Therapeutics
Abstract Session: Late Breaking 204
Date/Time: Friday, November 11, 2022, from 11:25 am – 11:55 am ET
Location: Hall B2, Omni Boston Hotel, Boston, MA or Virtual

27th Annual Meeting of the Society for Neuro-Oncology (SNO)

Oral Presentation Title: Enriched TCR/BCR VDJ rearrangements correlate with MRI and survival outcomes in patients with recurrent high-grade glioma treated with CAN-3110

Presenter: Alexander Ling, PhD, Postdoctoral Research Fellow, Brigham and Women’s Hospital
Abstract Session: Clinical Trial I
Date/Time: Friday, November 18, 2022, from 5:30 pm – 5:35 pm ET
Location: Ballroom B, Tampa Convention Center, Tampa, FL
Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies that elicit a systemic anti-tumor immune response. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. The enLIGHTEN™ Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “wil

[axelvento]

Candel Therapeutics Completes Enrollment in Phase 3 Clinical Trial of CAN-2409 in Combination with Valacyclovir for the Treatment of Intermediate-High Risk Localized Prostate Cancer


Furthermore, more than 700 patients have been dosed to date with a favorable safety profile, supporting the potential for combination with other therapeutic strategies without inordinate concern of overlapping adverse events. Currently, Candel is evaluating the effects of treatment with CAN-2409 in high-grade glioma, non-small cell lung cancer, pancreatic cancer, and prostate cancer in ongoing clinical trials.

[MiamiGent]

Good info, axel!
Thank you for sharing it.
MG

[axelvento]

this is very interesting: https://www.healthleadersmedia.com/pharma/just-two-years-helm-ceo-paul-peter-tak-transforms-candel-and-cancer-treatment




CAN-2409 is also being evaluated in multiple phase 2 and phase 3 clinical trials for lung, brain, pancreatic, and prostate cancers.

but we will have more new data and a new cohort of 11 patients in December this year."

[MiamiGent]

GL with Candel axel!
Let us know how you do.

MG

[axelvento]

Key Upcoming Milestones big news imminent$$$$$$$$......

In the fourth quarter of 2022, the Company expects to present new data from three clinical trials:
A phase 1b clinical trial of CAN-2409 in combination with nivolumab (Opdivo®) combined with standard of care in first line treatment in patients with high-grade glioma.
A phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma.
A phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 or PD-L1 agents in patients with stage III/IV NSCLC.
The Company anticipates initiating a phase 3 clinical trial evaluating CAN-2409 in patients with high-grade glioma in the third quarter of 2022.

[MiamiGent]

CADL is the #1 performing stock in the market this morning!

Top % gainers
As of Oct-21-2022 10:13 AM ET

Symbol Name Last Change Volume 90-day avg. volume 52-week range

CADL CANDEL THERAPEUTICS INC $1.87 +0.39 (+26.35%)
143.8K 19.4K
$1.48 - $11.98

ILAG INTELLIGENT LIVING APPLIC... $2.88 +0.53 (+22.55%)
3.4M 8.0M
$1.49 - $26.40

BTCY BIOTRICITY INC $1.17 +0.2196 (+23.11%)
1.4M 70.6K
$0.7500 - $5.30

VRE VERIS RESIDENTIAL INC $14.78 +2.3563 (+18.97%)
1.2M 540.3K
$10.22 - $19.90

BHVN BIOHAVEN LTD $13.97 +2.0074 (+16.78%)
3.9M 2.7M
$5.54 - $15.33

HA HAWAIIAN HOLDINGS INC $15.97 +1.89 (+13.42%)
1.3M 778.6K
$12.76 - $24.27

MTA METALLA ROYALTY & STREAMI... $4.50 +0.4757 (+11.83%)
176.5K 150.4K
$3.42 - $8.49

KOLD PROSHARES ULTRASHORT BLOO... $26.20 +2.72 (+11.58%) 1.9M 10.5M
$9.06 - $275.00

ASTI ASCENT SOLAR TECHNOLOGIES... $5.62 +0.50 (+9.77%) 1.4M 77.1K
$2.53 - $94.00

SAM BOSTON BEER COMPANY INC $373.01 +36.85 (+10.96%)
148.1K 156.3K
$287.00 - $547.71

CALT CALLIDITAS THERAPEUTICS A... $12.76 +1.2601 (+10.96%)
39.1K 6.9K
$10.82 - $27.50

BANF BANCFIRST CORP $100.97 +9.745 (+10.68%)
31.0K 153.9K
$62.66 - $118.07

NVAX NOVAVAX INC $18.94 +1.76 (+10.24%)
2.4M 6.1M
$16.00 - $236.50

MGNX MACROGENICS INC $4.45 +0.43 (+10.70%)
244.3K 1.1M
$2.13 - $22.68

RUM RUMBLE INC $7.79 +0.69 (+9.72%)
663.8K 2.1M
$6.35 - $18.52

ARLO ARLO TECHNOLOGIES INC $4.81 +0.405 (+9.20%)
217.3K 556.6K
$4.28 - $11.79

AMTB AMERANT BANCORP INC $28.50 +2.19 (+8.32%)
47.1K 74.6K
$24.41 - $36.72

SMPL SIMPLY GOOD FOODS CO $35.07 +2.69 (+8.31%)
321.1K 723.5K
$29.21 - $45.77

QTEK QUALTEK SERVICES INC $1.38 +0.105 (+8.27%)
12.0K 195.7K
$0.9700 - $10.43

KLXE KLX ENERGY SERVICES HOLDI... $13.06 +0.99 (+8.20%) 108.3K 234.3K
$2.94 - $13.36

HBAN HUNTINGTON BANCSHARES INC $14.28 +1.075 (+8.14%) 10.1M 15.3M
$11.67 - $17.79

ONG DIREXION DAILY OIL SERVIC... $31.00 +2.32 (+8.09%)
18.2K 19.8K
$16.68 -$47.24

BJRI BJS RESTAURANTS INC $28.97 +2.09 (+7.78%)
205.0K 354.7K
$20.15 - $37.64

SRCE 1ST SOURCE CORP $53.72 +3.86 (+7.74%)
18.7K 46.8K
$42.29 - $53.96

RERE ATRENEW INC $1.95 +0.14 (+7.73%)
222.8K 308.7K
$1.78 - $9.77

VAPO VAPOTHERM INC $1.21 +0.085 (+7.59%)
37.2K 228.3K
$0.9590 - $25.80

SLB SCHLUMBERGER NV $49.06 +3.3714 (+7.38%)
8.7M 13.1M
$27.65 - $49.83

NVVE NUVVE HOLDING CORP $1.18 +0.0799 (+7.26%)
38.8K 221.7K
$1.03 - $17.30

HTH HILLTOP HOLDINGS INC $26.83 +1.73 (+6.89%)
132.8K 560.0K
$24.18 - $38.47

NINE NINE ENERGY SERVICE INC $4.44 +0.30 (+7.25%)
130.6K 450.3K
$0.7940 - $8.10

[crudeoil24]

Candel Therapeutics, Inc, formerly Advantagene, Inc, is a clinical stage biopharmaceutical company. The Company is focused on helping patients fight cancer with oncolytic viral immunotherapies. Its engineered viruses are designed to induce immunogenic death through viral-mediated cytotoxicity in cancer cells, therefore releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Its approach combines a knowledge of viral immunotherapy with clinical experience across a range of indications. Its product candidate, CAN-2409 program, is in Phase III clinical trial. Its lead HSV product candidate, CAN-3110, is in Phase I clinical trial. The Company also designs candidates based on its HSV platform for the treatment of solid tumors. The Company’s oncolytic viral immunotherapy platforms is based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. Its preclinical models and clinical trials use its approach.